Recombinant Human CD19 (C-Fc)

Name: Recombinant Human CD19 (C-Fc)
SKU: RP00044

Cat.No. : RP00044 Tag: C-Fc

Expressed Region: Pro20-Lys291 Expression System: CHO Stable Cell

Inquire for Price

Product Details

Target Information

Cat. No.	RP00044
Description	The Recombinant Human CD19 (C-Fc) is produced in our CHO Stable Cell expression system. The amino acid region expressed is Pro20-Lys291 with a Fc tag at the C terminus.
Species	Human
Tag	C-Fc
Mol. Weight	57.3 KDa
Expressed Region	Pro20-Lys291
Expression System	CHO Stable Cell
Format	Powder
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
Conjugate	Unconjugated
Endotoxin Level	< 1 EU/µg of protein by LAL method
Purity	>95% as determined by SDS-PAGE. >90% as determined by SEC-MALS.
Shipping	The product is shipped with ice packs. Upon receipt, store it immediately at the temperature recommended below.
Storage	Upon receipt, this product is stable for up to 6 months at temperatures below -70°C. Once reconstituted, the product is stable for up to 1 week at 4°C and up to 3 months at -20°C. Please avoid repeated freeze-thaw cycles.
Reconstitution	Always centrifuge tubes before opening. It is recommended to reconstitute the solution to a concentration above 100 μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

Target Gene	CD19
Background	This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
Synonyms	B-Lymphocyte Antigen CD19; B-Lymphocyte Surface Antigen B4; Differentiation Antigen CD19; T-Cell Surface Antigen Leu-12; CD19

Quick Inquiry

Publications

Q & A

Customer Reviews

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

First Name

Country *

Email *

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *